Objective:To evaluate the effect of resveratrol on ferropotosis in cardiomyocytes of mice with diabetic cardiomyopathy.Methods:Thirty healthy adult male C57BL/6 mice, aged 8 weeks, weighing 22-26 g, were divided into 3 groups ( n=10 each) using a random number table method: control group (group C), diabetic cardiomyopathy group (group DCM) and resveratrol group (group RSV). Freshly prepared streptozotocin (STZ) 40 mg·kg -1·d -1 was intraperitoneally injected for 5 consecutive days to develop the model of type 1 diabetes mellitus. After the model was successfully developed, resveratrol 25 mg·kg -1·d -1 was intragastrically given for 12 consecutive weeks in group RSV, while the equal volume of dimethyl sulfoxide was given instead in group C and group DCM. Echocardiography was performed to examine the cardiac structure and function at the end of the 12th week. Then mice were sacrificed, and myocardial tissue specimens were harvested for microscopic examination of the pathological changes of myocardial tissues (by Hematologist-Eosin staining) and mitochondrial morphology of myocardial cells (with a transmission electron microscope) and for determination of the contents of iron, malondialdehyde (MDA) and glutathione (GSH) (by colorimetry) and expression of glutathione peroxidase 4 (GPX4) (by Western blot). Results:Compared with group C, the left ventricular end-diastolic diameter and left ventricular end-systolic diameter were significantly increased, the left ventricular ejection fraction and left ventricular fractional shortening were decreased, the contents of iron and MDA were increased, the content of GSH was decreased, and the expression of GPX4 was down-regulated in group DCM ( P<0.05). Compared with group DCM, the left ventricular end-diastolic diameter and left ventricular end-systolic diameter were significantly decreased, the left ventricular fractional shortening and ejection fraction were increased, the contents of iron and MDA were decreased, the content of GSH was increased, the expression of GPX4 was up-regulated ( P<0.05), and the pathological changes of myocardial tissues and changes in mitochondrial morphology of myocardial cells were significantly attenuated in group RSV. Conclusions:The mechanism by which resveratrol attenuates myocardial injury and further improves cardiac dysfunction is related to inhibition of ferroptosis in cardiomyocytes of mice with diabetic cardiomyopathy.

Objective:To investigate the expression of syndecan-1 (SDC1) in human venous malformations and the effect of syndecan-1 (SDC1) silences on migration, invasion and angiogenesis of human umbilical vein endothelial cells (HUVECs).Methods:Pathological samples of venous malformation were selected from 20 patients with hemangioma surgically resected in the Third Affiliated Hospital of Zhengzhou University from December 2020 to June 2021 (10 males and 10 females, aged 1-57 years, median age 7 years ). HUVECs was purchased from American Type Culture Collection (ATCC ). Immunohistochemistry was used to detect the expression of SDC1 in venous malformations. The cytological experiments of HUVECs cultured in vitro were divided into two groups, transfected SDC1 small interfering RNA (siRNA) (si-SDC1 group) and control siRNA (control group), respectively. The siRNA with the best silencing effect was selected by real-time quantitative PCR and Western Blot method for follow-up experiments. Then the ability of HUVECs migration, invasion and angiogenesis was detected by scratch test, Transwell migration and invasion test and angiogenesis test, respectively.Results:SDC1 was positive in 13 of the 20 venous malformations and was mainly expressed in the cytoplasm of venous endothelial cells. Compared with HUVECs cells in NC group, the expression of SDC1 mRNA and protein in HUVECs cells in si-SDC1 group decreased, indicated that the synthesized siRNA targeting SDC1 could silence the expression of SDC1 , and the ability of HUVECs migration, invasion and angiogenesis were enhanced in si-SDC1 group.Conclusions:SDC1 was positively expressed in venous malformations. After silencing SDC1, the migration, invasion and tube formation ability of HUVECs were enhanced.

Objective:To investigate the expression of syndecan-1 (SDC1) in human venous malformations and the effect of SDC1 silencing on the migration, invasion and angiogenesis abilities of human umbilical vein endothelial cells (HUVECs).Methods:Twenty surgically resected samples of venous malformation were collected from 20 patients with hemangioma at the Third Affiliated Hospital of Zhengzhou University from December 2020 to June 2021 (10 males and 10 females, aged 1-57 years, median age 7 years). HUVECs were purchased from American Type Culture Collection (ATCC). Immunohistochemistry staining was used to detect the expression of SDC1 in venous malformations. HUVECs cultured in vitro were divided into two groups, and were transfected with SDC1 small interfering RNA (siRNA) (si-SDC1 group) or control siRNA (control group), respectively. The siRNA with the best silencing effect was screened and tested by real-time quantitative PCR and Western blotting for follow-up experiments. The migration, invasion and angiogenesis abilities of HUVECs were measured by scratch test, Transwell migration and invasion test, and angiogenesis test, respectively. Results:(1) SDC1 was positive in 13(65.0%) of the 20 venous malformations and was mainly expressed in the cytoplasm of venous endothelial cells. (2) Compared with HUVECs in the control group, the expression of SDC1 mRNA and protein in HUVECs cells in si-SDC1 group both decreased ( P<0.05), indicating the synthesized siRNA targeting SDC1 could silence the expression of SDC1. (3) The migration, invasion and angiogenesis abilities of HUVECs were enhanced in si-SDC1 group( P<0.05). Conclusions:SDC1 was expressed in most venous malformations. After silencing SDC1, the migration, invasion and tube formation abilities of HUVECs were enhanced.

Objective:To investigate the expression of syndecan-1 (SDC1) in human venous malformations and the effect of syndecan-1 (SDC1) silences on migration, invasion and angiogenesis of human umbilical vein endothelial cells (HUVECs).Methods:Pathological samples of venous malformation were selected from 20 patients with hemangioma surgically resected in the Third Affiliated Hospital of Zhengzhou University from December 2020 to June 2021 (10 males and 10 females, aged 1-57 years, median age 7 years ). HUVECs was purchased from American Type Culture Collection (ATCC ). Immunohistochemistry was used to detect the expression of SDC1 in venous malformations. The cytological experiments of HUVECs cultured in vitro were divided into two groups, transfected SDC1 small interfering RNA (siRNA) (si-SDC1 group) and control siRNA (control group), respectively. The siRNA with the best silencing effect was selected by real-time quantitative PCR and Western Blot method for follow-up experiments. Then the ability of HUVECs migration, invasion and angiogenesis was detected by scratch test, Transwell migration and invasion test and angiogenesis test, respectively.Results:SDC1 was positive in 13 of the 20 venous malformations and was mainly expressed in the cytoplasm of venous endothelial cells. Compared with HUVECs cells in NC group, the expression of SDC1 mRNA and protein in HUVECs cells in si-SDC1 group decreased, indicated that the synthesized siRNA targeting SDC1 could silence the expression of SDC1 , and the ability of HUVECs migration, invasion and angiogenesis were enhanced in si-SDC1 group.Conclusions:SDC1 was positively expressed in venous malformations. After silencing SDC1, the migration, invasion and tube formation ability of HUVECs were enhanced.

Objective:To investigate the expression of syndecan-1 (SDC1) in human venous malformations and the effect of SDC1 silencing on the migration, invasion and angiogenesis abilities of human umbilical vein endothelial cells (HUVECs).Methods:Twenty surgically resected samples of venous malformation were collected from 20 patients with hemangioma at the Third Affiliated Hospital of Zhengzhou University from December 2020 to June 2021 (10 males and 10 females, aged 1-57 years, median age 7 years). HUVECs were purchased from American Type Culture Collection (ATCC). Immunohistochemistry staining was used to detect the expression of SDC1 in venous malformations. HUVECs cultured in vitro were divided into two groups, and were transfected with SDC1 small interfering RNA (siRNA) (si-SDC1 group) or control siRNA (control group), respectively. The siRNA with the best silencing effect was screened and tested by real-time quantitative PCR and Western blotting for follow-up experiments. The migration, invasion and angiogenesis abilities of HUVECs were measured by scratch test, Transwell migration and invasion test, and angiogenesis test, respectively. Results:(1) SDC1 was positive in 13(65.0%) of the 20 venous malformations and was mainly expressed in the cytoplasm of venous endothelial cells. (2) Compared with HUVECs in the control group, the expression of SDC1 mRNA and protein in HUVECs cells in si-SDC1 group both decreased ( P<0.05), indicating the synthesized siRNA targeting SDC1 could silence the expression of SDC1. (3) The migration, invasion and angiogenesis abilities of HUVECs were enhanced in si-SDC1 group( P<0.05). Conclusions:SDC1 was expressed in most venous malformations. After silencing SDC1, the migration, invasion and tube formation abilities of HUVECs were enhanced.

Levetiracetam (LEV) is the second generation of broad-spectrum antiepileptic drugs. Compared with other antiepileptic drugs, LEV has unique antiepileptic mechanism, good efficacy and tolerance, and its target is synaptic vesicle protein 2A. With the widespread use of LEV, more and more adverse reactions have been reported, especially mental related adverse reactions. This paper reviewed the research progress of LEV pharmacogenomics related targets, metabolism, adverse reaction related genetic variation and efficacy prediction, so as to provide decision-making for the application of LEV individualized treatment in clinical practice, improve the quality of life of epileptic patients and reduce the disease burden of patients with epilepsy.

Objective:To evaluate the therapeutic effect of radiofrequency ablation in the treatment of severe hemangioma with thrombocytopenia and coagulation abnormality (Kasabach-Merritt phenomenon, KMP).Methods:From April 2018 to April 2021, 11 cases of KMP in our department were retrospectively analyzed. The patients underwent MRI, color ultrasound and hematology examination. Radiofrequency ablation was performed for all patients under general anesthesia. The comprehensive, multi-level and multi-point ablation was accurately implemented under the whole-process intraoperative monitoring of color ultrasound. Postoperative ice pad was applied for the treatment area, and dressing change was carried out every day.Results:All 11 cases of KMP were treated with radiofrequency ablation, including 5 males and 6 females, aged 1 d to 2 months, with a median age of 15 d. Intraoperative color Doppler ultrasound monitoring showed that the tumor was completely ablated in the single operation. All patients were followed up for 0.5 to 2 years. The tumor was cured without recurrence. The local function was unaffected. The local scar formation was mild and the appearance was satisfactory.Conclusions:Radiofrequency ablation has great clinical value in the treatment of KMP. It makes up the shortcomings and avoids the disadvantages of traditional surgery and other conservative treatment methods. Good clinical results can be achieved by radiofrequence ablation with satifactory function and appearance.

Objective:To evaluate the therapeutic effect of radiofrequency ablation in the treatment of severe hemangioma with thrombocytopenia and coagulation abnormality (Kasabach-Merritt phenomenon, KMP).Methods:From April 2018 to April 2021, 11 cases of KMP in our department were retrospectively analyzed. The patients underwent MRI, color ultrasound and hematology examination. Radiofrequency ablation was performed for all patients under general anesthesia. The comprehensive, multi-level and multi-point ablation was accurately implemented under the whole-process intraoperative monitoring of color ultrasound. Postoperative ice pad was applied for the treatment area, and dressing change was carried out every day.Results:All 11 cases of KMP were treated with radiofrequency ablation, including 5 males and 6 females, aged 1 d to 2 months, with a median age of 15 d. Intraoperative color Doppler ultrasound monitoring showed that the tumor was completely ablated in the single operation. All patients were followed up for 0.5 to 2 years. The tumor was cured without recurrence. The local function was unaffected. The local scar formation was mild and the appearance was satisfactory.Conclusions:Radiofrequency ablation has great clinical value in the treatment of KMP. It makes up the shortcomings and avoids the disadvantages of traditional surgery and other conservative treatment methods. Good clinical results can be achieved by radiofrequence ablation with satifactory function and appearance.

Objective To assess the clinical value of preoperative CT-guided microcoil positioning of small solitary pulmonary nodule (SPN) in assisting video-assisted thoracic surgery (VATS) procedure to more quickly and more precisely remove small pulmonary lesions.Methods The clinical data of 90 patients with SPN,who were admitted to authors' hospital during the period from June 2014 to May 2016 to receive VATS,were retrospective analyzed.Preoperative CT-guided microcoil positioning of SPN was employed in 45 patients (group A),while other 45 patients (group B) did not receive preoperative positioning of SPN.The pulmonary lobar wedge resection time,the transfer rate of changing to open chest operation,postoperative hospitalization time,the success rate of microcoil positioning of SPN,complications,etc.of both groups were statistically analyzed.The safety of preoperative CT-guided microcoil positioning of SPN was evaluated,and its benefit-enhancing value for VATS was discussed.Results In group A,the success rate of VATS was 100％ and the success rate of SPN positioning was 95.6％.Postoperative complications included pneumothorax (n=5),pulmonay surface hemorrhage (n=6),and dislodgement of microcoil (n=2).In group B,the success rate of VATS was 84.4％ and the transfer rate of changing to open chest operation was 15.6％.In group A,the manipulation time of VATS was (17.7±2.8) min,the postoperative hospitalization time was (6.2±1.7) days,and the transfer rate of changing to open chest operation was 0％,which were strikingly lower than those in group B;the differences between the two groups were statistically significant (P＜0.05).Conclusion Preoperative CT-guided microcoil positioning of small SPN can assist VATS procedure to remove small pulmonary lesions more quickly and more precisely,it can effectively reduce the transfer rate of changing to open chest operation,shorten the manipulation time of VATS as well as the postoperative hospitalization time.

Background The pathology of choroidal neovascularization (CNV) is not clear.CD147 plays a critical role in angiogenesis through activating matrix metalloproteinases (MMPs) and degradation of extracellular matrix (ECM).However,the study of CD147 in CNV is rare.Objective This study was to investigate the expression of CD147 and vascular endothelial growth factor (VEGF) in laser-induced rat CNV model.Methods Thirty clean BN rats were divided into normal control group (six rats) and laser group (24 rats) according to the random number table.CNV was induced on laser photocoagulation group rats using 532 nm multiple-wave length photocoagulation.The development of CNV was followed up by fundus fluorescence angiography (FFA) on 1 day,7,14 and 21 days post-photocoagulation.The expression of C D147 protein in retinal pigment epithelium (RPE)-choroidsclera complex was examined by Western blot in normal control group and 1 day,7,14,21 days post-photocoagulation group.The vitreous VEGF concentrations of those groups were detected by ELISA.Results Disk like fluorescein leakage was detected on 7 days after photocoagulation,and CNV was formed on 14 days after photocoagulation.The expressions of CD147 protein were 1.00 ± 0.43,0.97 ± 0.53,0.99 ± 0.45,1.56 ± 0.67 and 2.27 ± 0.54,and the concentrations of vitreous VEGF were (72.96±29.95),(79.36±10.46),(103.82±32.94),(166.05±21.54) and (195.64± 39.90)pg/ml in normal control group and 1 day,7,14,21 days post-photocoagulation group,with significant differences among the groups (CD147:F=10.95,P＜0.01;VEGF:F=304.50,P＜0.01).The expressions of CD147 and VEGF were significantly higher in the 14,21 days post-photocoagulation groups than those in the normal control group (all at P＜0.05).Conclusions The expression of CD147 increases as the induction of CNV,in accordance with the expression of VEGF.CD147 may play an important role in the early development of CNV.